Machine Learning Company Wants to Increase Use of Adaptive Trial Design
Using machine learning, PhaseV, an Israeli startup is trying to make adaptive trial design more accessible. It is early days, but the company's approach is attracting investors and partners.
You may also be interested in...
Israeli start-up 9xchange is removing some of the friction from the asset sale and acquisition process through its digital marketplace. A partnership with BenevolentAI is also helping users identify repurposing or indication expansion opportunities. In Vivo spoke with 9xchange CEO Anat Naschitz and Benevolent AI's Matthew Fujisawa.
Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead.
Companies making blood-based cancer screening tests face a number of barriers to full market entry but getting a foothold of any kind can be the start of a path towards greater ultimate uptake.